Mark Leonard Singleton - Mar 21, 2024 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & CFO
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Mar 21, 2024
Transactions value $
-$29,853
Form type
4
Date filed
3/25/2024, 05:36 PM
Previous filing
Mar 22, 2024
Next filing
Apr 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +18.6K +148.04% 31.2K Mar 21, 2024 Direct F1
transaction BVS Class A Common Stock Sale -$29.9K -5.54K -17.76% $5.39 25.7K Mar 22, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -18.6K -33.33% $0.00 37.3K Mar 21, 2024 Class A Common Stock 18.6K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 Reflects shares sold to cover taxes upon the vesting of restricted stock units on March 21, 2024 pursuant to a standing 10b5-1 instruction.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.36 to $5.43, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The original grant of 74,500 RSUs vests in four approximately equal annual installments that began on March 21, 2023.